Beta blockers are a recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF). Beta blockers markedly and unequivocally reduce mortality in patients with heart failure with reduced ejection fraction. However, the beneficial effects of beta blockers in patients with heart failure with preserved ejection fraction(HFpEF) are not well established. In this review, we will assess the evidence basis of the recommendations for beta blockers and discuss emerging concerns about the use of beta blockers in patients with HFpEF. The available evidence for beta blockers is limited and it remains uncertain whether beta blockers have a beneficial role in the treatment of HFpEF in the absence of an alternative indication for their use. (C) 2019 Published by Elsevier B.V.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81873512, 81471021]
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Div Cardiol,Dept Internal Med, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China[2]Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430030, Hubei, Peoples R China
通讯作者：
通讯机构：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Div Cardiol,Dept Internal Med, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China[2]Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430030, Hubei, Peoples R China
推荐引用方式(GB/T 7714)：
Xu Xizhen,Wang Dao Wen.The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction[J].IJC HEART & VASCULATURE.2020,26:doi:10.1016/j.ijcha.2019.100451.
APA：
Xu, Xizhen&Wang, Dao Wen.(2020).The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction.IJC HEART & VASCULATURE,26,
MLA：
Xu, Xizhen,et al."The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction".IJC HEART & VASCULATURE 26.(2020)
